From arginine methylation to ADMA: A novel mechanism with therapeutic potential in chronic lung diseases
2009

Arginine Methylation and Its Role in Chronic Lung Diseases

publication Evidence: moderate

Author Information

Author(s): Zakrzewicz Dariusz, Eickelberg Oliver

Primary Institution: University of Giessen Lung Center

Hypothesis

Dysregulated arginine methylation contributes to the pathogenesis of chronic lung diseases.

Conclusion

Dysregulated arginine methylation is implicated in the development of chronic lung diseases, suggesting potential therapeutic targets.

Supporting Evidence

  • ADMA and MMA are endogenous inhibitors of nitric oxide synthases.
  • Elevated ADMA concentrations have been detected in the plasma of patients with pulmonary arterial hypertension.
  • Disrupted methylarginine metabolism impairs vascular homeostasis in pulmonary arterial hypertension.

Takeaway

This study talks about how a process called arginine methylation can go wrong and lead to lung diseases. By fixing this process, we might be able to help people with these diseases.

Methodology

The review discusses recent findings and mechanisms related to arginine methylation in chronic lung diseases.

Limitations

The review does not provide new experimental data but summarizes existing literature.

Digital Object Identifier (DOI)

10.1186/1471-2466-9-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication